ω-3 Docosahexaenoic Acid (DHA) Epoxide Generation via CYP2J2 to Protect Synaptic Membranes from Aβ-Induced Rigidification
🧪 Overview
The hypothesis proposes that ω-3 docosahexaenoic acid (DHA) is metabolized by CYP2J2 to generate protective epoxides that shield synaptic membranes from amyloid-beta (Aβ)-induced rigidification. Evidence from planar lipid bilayer experiments demonstrates that CYP2J2-derived epoxides mitigate Aβ-induced membrane rigidity (pmid:31243156). Aβ oligomers are known to increase membrane cholesterol content by approximately 40% and expand raft domain size in cortical neurons (pmid:24503041). Supporting this mechanism, DHA supplementation in 5xFAD mouse models reduces Aβ burden and improves synaptic plasticity markers (pmid:29982765). However, critical uncertainties exist: epoxides are rapidly metabolized by soluble epoxide hydrolase (sEH) with plasma half-lives of 2-4 hours, presenting a significant pharmacokinetic challenge (pmid:31243156). Additionally, the protective membrane fluidity model has only been validated in artificial planar bilayers, not in native neuronal membranes (Skeptic critique).
...🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["DHA Substrate Pool<br/>Membrane Omega-3 Lipids"]
B["CYP2J2 Epoxygenase<br/>DHA-to-Epoxide Conversion"]
C["Epoxy-DHA Mediators<br/>Anti-inflammatory Lipid Signals"]
D["sEH Inhibition<br/>Epoxide Lifetime Prolonged"]
E["Synaptic Membrane Fluidity<br/>A-beta-Induced Rigidification Blocked"]
F["Excitatory Signaling Stability<br/>Receptor Mobility Preserved"]
G["Synaptic Protection<br/>Reduced A-beta Toxicity"]
A --> B
B --> C
D --> C
C --> E
E --> F
F --> G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style G fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
🏥 Translation
🧬 3D Protein Structure — CYP2J2
No curated PDB or AlphaFold mapping for CYP2J2 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CYP2J2/ω-3 DHA epoxides (sEH inhibition) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CYP2J2.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF human iPSC-derived cortical neurons are incubated with a blood-brain barrier-penetrant soluble epoxide hydrolase (sEH) inhibitor (e.g., 1 µM GSK218) for 24 h prior to 72 h co-exposure with 1 µM Aβ( | AFM indentation modulus increased by ≥30% (indicating decreased rigidity) in sEH-inhibitor–treated neurons exposed to Aβ, reflecting protection against Aβ-induc | — no observation — | pending | 0.65 |
| IF primary cortical neurons from APP/PS1 mice are pretreated with a selective CYP2J2 inhibitor (e.g., 10 µM compound) for 2 h before a 48 h exposure to 2 µM Aβ(1-42) THEN the mean Laurdan generalized | Increased Laurdan GP (≥0.10 units) indicating greater membrane rigidification in CYP2J2-inhibited, Aβ-exposed neurons. | — no observation — | pending | 0.68 |
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |